Onfi

Onfi is a brand name of clobazam, approved by the FDA in the following formulation(s):

ONFI (clobazam - tablet; oral)

• 
  Manufacturer: LUNDBECK INC
  
  Approval date: October 21, 2011
  
  Strength(s): 10MG, 20MG ^[RLD], 5MG
  

Has a generic version of Onfi been approved?

No. There is currently no therapeutically equivalent version of Onfi available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Onfi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Onfi.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • October 21, 2016 - NEW CHEMICAL ENTITY
  
  
  • October 21, 2018 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Onfi Consumer Information (Drugs.com)
• Onfi Consumer Information (Wolters Kluwer)
• Onfi Consumer Information (Cerner Multum)
• Clobazam Consumer Information (Wolters Kluwer)
• Clobazam Consumer Information (Cerner Multum)